Idrinol, 100 mg/ml 5 ml 10 pcs

IDRINOL is a metabolism-improving agent, an analogue of gamma-butyrobetaine. Inhibits gamma-butyrobetaine hydroxinase, inhibits carnitine synthesis and transport of long-chain fatty acids through cell membranes, prevents accumulation of activated forms of non-oxidized fatty acids in cells – derivatives of acylcarnitine and acylkoenzyme A.

In conditions of ischemia it restores the balance of oxygen delivery and consumption in cells, prevents the disruption of ATP transport; at the same time it activates glycolysis, which proceeds without additional oxygen consumption. As a result of decrease of carnitine concentration, gamma-butyrobetaine, which has vasodilatory properties, is synthesized intensively. The mechanism of action determines the diversity of its pharmacological effects: increase of work capacity, reduction of symptoms of mental and physical overexertion, activation of tissue and humoral immunity, cardioprotective effect.

In case of acute myocardial ischemic injury it slows down the formation of the necrotic zone and shortens the rehabilitation period. In cardiac insufficiency it increases myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks.

In acute and chronic ischemic cerebral circulatory disorders improves blood circulation in the focus of ischemia, helps redistribute blood in favor of the ischemic area. It is effective for vascular and dystrophic ocular fundus pathology. It has a tonic effect on the central nervous system, eliminates the functional disorders of the nervous system in patients with chronic alcoholism in withdrawal syndrome.

Indications

For oral administration or intravenous injection: in complex therapy of CHD (angina pectoris, myocardial infarction), chronic heart failure, dishormonal cardiomyopathy; in complex therapy of acute and chronic cerebrovascular disorders (strokes and cerebrovascular failure); reduced work capacity, physical overexertion (incl. athletes).in athletes), postoperative period to accelerate rehabilitation; withdrawal syndrome in chronic alcoholism (in combination with specific alcohol therapy).

For parabulbar injection: acute circulatory disorders in the retina, hemophthalmia and retinal hemorrhages of different etiology, central retinal vein thrombosis and its branches, retinopathies of different etiology (including diabetic and hypertensive) – only for parabulbar injection.

Active ingredient

Composition

Active ingredient:

Meldonium dihydrate without adsorbed moisture – 100 mg (in terms of meldonium anhydrous – 80.21 mg);

auxiliary substances:

water for injection.

How to take, the dosage

In connection with the possibility of development of excitatory effect it is recommended to use in the morning. The dose is set individually depending on the indication and route of administration.

In oral administration the single dose is 0.25-1 g; the frequency of administration and duration of treatment depend on the indication.

Intravenous doses are 0.5-1 g once daily, the duration of therapy depends on the indication.

Parabulbarrelly, 0.5 ml of 500 mg/5 ml solution for injection for 10 days.

Interaction

When used together, meldonium increases the effect of antianginal drugs, some hypotensive drugs, and cardiac glycosides.

In concomitant use of meldonium with nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive agents and peripheral vasodilators, moderate tachycardia and arterial hypotension may develop (caution is required with these combinations).

Special Instructions

Idrinol is not a first-line drug for acute coronary syndrome.

Idrinol has no effect on the ability to drive and operate machinery:

There are no data on adverse effects of the drug Idrinol on the speed of psychomotor reactions.

Contraindications

Elevated intracranial pressure (including venous outflow disorders, intracranial tumors), pregnancy, lactation (breastfeeding), hypersensitivity to meldonium.

Side effects

Cardiovascular system: rare – tachycardia, decreased or increased BP.

CNS disorders: rarely – psychomotor agitation.

Digestive system disorders: rare – dyspeptic disorders.

Allergic reactions: rare – skin itching, rash, cutaneous hyperemia, angioedema; very rare – eosinophilia.

Others: very rare – general weakness.

Overdose

Symptoms: decreased BP accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: symptomatic

Similarities